Back to top
more

Lineage Cell Therapeutics, Inc. (LCTX)

(Delayed Data from AMEX)

$1.54 USD

1.54
1,214,568

+0.02 (1.32%)

Updated Dec 3, 2020 04:00 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.41%
2Buy17.88%
3Hold9.48%
4Sell5.03%
5Strong Sell1.87%
S&P50010.70%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 19% (205 out of 254)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

Lineage Cell (LCTX) Reports Q3 Loss, Lags Revenue Estimates

Lineage Cell (LCTX) delivered earnings and revenue surprises of 20.00% and -12.15%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Pacira's (PCRX) Q1 Earnings Top Estimates, Revenues Rise Y/Y

Pacira (PCRX) beats on both earnings and revenues in the first quarter of 2020. The company temporarily suspends 2020 guidance in the wake of the COVID-19 pandemic.

Editas' (EDIT) Earnings Beat in Q1, Revenues Improve Y/Y

Editas (EDIT) beats on earnings in the first quarter of 2020 while revenues slightly miss estimates.

ACADIA's (ACAD) Q1 Earnings & Revenues Fall Shy of Estimates

ACADIA's (ACAD) earnings and sales lag estimates in the first quarter of 2020. The company trims its 2020 revenue guidance due to the coronavirus impact. Stock declines in after-hours trading.

Is Lineage Cell Therapeutics (LCTX) Outperforming Other Medical Stocks This Year?

Is (LCTX) Outperforming Other Medical Stocks This Year?

Lineage Cell (LCTX) to Post Q1 Earnings: What's in the Cards?

On Lineage Cell's (LCTX) Q1 earnings call, investor focus will be on its progress with the pipeline candidate OpRegen, currently being developed for treating dry AMD, as well as other pipeline updates.

Will Lineage Cell Therapeutics Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor Lineage Cell Therapeutics

Earnings Preview: Lineage Cell (LCTX) Q1 Earnings Expected to Decline

Lineage Cell (LCTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Lineage Cell Therapeutics Sees Hammer Chart Pattern: Time to Buy?

Lineage Cell Therapeutics, Inc. (LCTX) has been struggling lately, but the selling pressure may be coming to an end soon.

Aytu BioScience (AYTU) in Focus: Stock Moves 6.4% Higher

Aytu BioScience (AYTU) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Lineage Cell (LCTX) Reports Q4 Loss, Tops Revenue Estimates

Lineage Cell (LCTX) delivered earnings and revenue surprises of 57.14% and 108.57%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Lineage Cell (LCTX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Lineage Cell (LCTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioTime, Inc. (LCTX) Upgraded to Strong Buy: Here's Why

BioTime, Inc. (LCTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Lineage Cell (LCTX) Reports Q3 Loss, Lags Revenue Estimates

Lineage Cell (LCTX) delivered earnings and revenue surprises of 20.00% and -39.68%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?